• Industries
    • Chemicals
    • Cosmetic & Consumer Products
    • Pharmaceuticals & Medical Devices
    • Biocides
  • Services
    • Chemical and Product Safety
    • Regulatory Strategy and Compliance
    • QSAR Modelling
    • New Approach Methodologies
    • Endocrine disruption
    • Product Stewardship
    • Environmental Risk Assessment of Medicinal Products
  • Team
    • Team
    • Collaborations
  • Insights
    • Insights
    • Cases
    • Publications
  • Careers
  • Contact
  • Industries
    • Chemicals
    • Cosmetic & Consumer Products
    • Pharmaceuticals & Medical Devices
    • Biocides
  • Services
    • Chemical and Product Safety
    • Regulatory Strategy and Compliance
    • QSAR Modelling
    • New Approach Methodologies
    • Endocrine disruption
    • Product Stewardship
    • Environmental Risk Assessment of Medicinal Products
  • Team
    • Team
    • Collaborations
  • Insights
    • Insights
    • Cases
    • Publications
  • Careers
  • Contact
  • You are here:
  • Home
  • Insights
  • EFSA/ECHA (2018) guidance for the identification of endocrine disruptors (ED): looking back after the first 3 years of implementation

EFSA/ECHA (2018) guidance for the identification of endocrine disruptors (ED): looking back after the first 3 years of implementation

Guidance for the assessment of endocrine disrupting (ED) properties under the Biocidal Products and Plant Protection Product Regulations (BPR and PPPR) was published in 2018 by the European Food Safety Authorities (EFSA) and the European Chemicals Agency (ECHA)1. Adaptations of the European Chemicals and Classification & Labelling Regulations (REACH2 and CLP3) are planned, in line with the EFSA/ECHA guidance. Today, there is no guidance for the ED assessment of chemicals, cosmetics, pharmaceuticals, and other types of substances but the ECHA/EFSA guidance may be used to frame also these evaluations.

In the European regulatory context, effects on the endocrine system are evaluated considering the estrogen (E), androgen (A), thyroid (T), and steroidogenesis (S) pathways, commonly referred to as the ‘EATS modalities’.

This poster looks at some of the issues encountered over the past three years when conducting guideline-compliant ED assessments across various types of chemistries.

READ MORE ON THE PDF
Author
  • Ms. Sanghamitra Mishra

    Ms. Sanghamitra Mishra

  • Dr. Monica Autiero

    Dr. Monica Autiero

  • Ms. Neha Barai

    Ms. Neha Barai

  • Dr. Thomas Petry

    Dr. Thomas Petry

  • Dr. Francesca Tencalla

    Dr. Francesca Tencalla

MORE INSIGHTS
  • Assessing cosmetic ingredients for endocrine disrupting properties

  • The importance of having a solid PC data package to support human health/environmental risk assessment and read across under REACH

  • Using (Q)SAR and read across to evaluate the toxicological risks of data-poor drug impurities and extractables/leachables

The importance of having a solid PC data package to support human health/environmental risk assessment and read across under REACH

Previous thumb

Assessing cosmetic ingredients for endocrine disrupting properties

Next thumb
Scroll

 

ToxMinds are specialised in ensuring product safety and compliance.

We are passionate about toxicology and how emerging scientific developments can be utilised to support our customers in bringing safe, regulatory compliant and sustainable products to the marketplace.

 

 

 

 

Belgium
ToxMinds BV
Avenue de Tervueren 188A, bte 12
B-1150 Brussels Belgium

VAT BE 0877.628.383

Tel: +32 (0)2 762 9145
Email: contact us

 

 

 

 

India
ToxMinds India Consulting Pvt. Ltd.
Unit 305, 3rd Floor, Brigade IRV Centre, Whitefield, Bangalore-560066, India

 

Tel: +91 804 204 19 20
Email: contact us

 

 

 

 

 

LinkedIN
Copyright and disclaimer | Data privacy
  • Home
  • Industries
  • Services
  • Team
  • Insights
  • Careers
  • Contact
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok